US 12,084,691 B2
Modulating human Cas9-specific host immune response
Radwa Ewaisha, Tempe, AZ (US); Samira Kiani, Scottsdale, AZ (US); Shayesteh Roshdi Ferdosi, Tempe, AZ (US); Karen Anderson, Scottsdale, AZ (US); Farzaneh Moghadam, Tempe, AZ (US); Sri Krishna, Tempe, AZ (US); and Mo Reza Ebrahimkhani, Scottsdale, AZ (US)
Assigned to ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY, Scottsdale, AZ (US)
Filed by Arizona Board of Regents on behalf of Arizona State University, Scottsdale, AZ (US)
Filed on Dec. 9, 2021, as Appl. No. 17/546,810.
Application 17/546,810 is a division of application No. 16/632,782, granted, now 11,208,640, previously published as PCT/US2018/029937, filed on Apr. 27, 2018.
Claims priority of provisional application 62/556,061, filed on Sep. 8, 2017.
Claims priority of provisional application 62/535,516, filed on Jul. 21, 2017.
Prior Publication US 2022/0162574 A1, May 26, 2022
Int. Cl. C12N 9/22 (2006.01); A61K 48/00 (2006.01); G01N 33/573 (2006.01)
CPC C12N 9/22 (2013.01) [G01N 33/573 (2013.01); A61K 48/00 (2013.01); C12N 2310/20 (2017.05); C12N 2800/80 (2013.01); G01N 2333/922 (2013.01)] 3 Claims
 
1. A variant Cas9 protein comprising the amino acid sequence of SEQ ID NO: 3 or the amino acid sequence of SEQ ID NO: 4, wherein said variant Cas9 protein has nuclease activity.